Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Food and Drug Administration

          - [FDA 225-06-8403]

# AGENCY:

Food and Drug Administration, HHS.

# ACTION:

Notice.

# SUMMARY:

                        The purpose of this Memorandum of Understanding (MOU) is to set forth an agreement between the National Cancer Institute (NCI), the National Institute of Standards and Technology (NIST), and the Food and                               ( print page 50073)                            Drug Administration (FDA) (collectively “the Parties”, or individually as a “Party”) regarding the roles, responsibilities, and financial commitments of each Party relating to the collaboration through working groups and steering committees to develop strategic plans, set priorities, and leverage resources and expertise from multiple sources, including the private sector, toward the goal of facilitating the development of nanotechnologies that constitute novel research tools and safer, more effective cancer therapies by establishing a framework for effective risk identification, assessment and evaluation of emerging products based on nanotechnology.  This collaboration among the Parties will be focused primarily on the Nanotechnology Characterization Laboratory and directly related activities.                    

# DATES:

The agreement became effective June 22, 2006.

# FOR FURTHER INFORMATION CONTACT:

*For FDA*:  Wendy R. Sanhai, Senior Scientific Advisor, Office of the Commissioner (HF-18), Food and Drug Administration, 5600 Fishers Lane,  Rockville, MD  20857, 301-827-7867,  FAX:  301-443-9718.                    

*For NCI*:  Gregory J. Downing, Director, Office of Technology and Industrial Relations, Office of the Director, National Cancer Institute, 31 Center Dr., rm. 10A52, Bethesda, MD  20892, 301-496-1550,  FAX: 301-496-7807.                    

*For NIST*:  Debra Kaiser,  Chief, Ceramics Division, Materials Science and Engineering Laboratory, National Institute of Standards and Technology, 100 Bureau Dr., Stop 8522, Gaithersburg, MD  20899, 301-975-6119, FAX: 301-975-5334.                    

# SUPPLEMENTARY INFORMATION:

                    In accordance with 21 CFR 20.108(c), which states that all written agreements and MOUs between FDA and others shall be published in the                     **Federal Register**                    , the agency is publishing notice of this MOU.                

Dated: August 16, 2006.

Jeffrey Shuren,

Assistant Commissioner for Policy.

      ( print page 50074)          ( print page 50075)          ( print page 50076)          ( print page 50077)    

BILLING CODE 4160-01-S

[FR Doc. 06-7127 Filed 8-23-06; 8:45 am]

BILLING CODE 4160-01-C